- Hormone therapy in addition to radiation can improve the survival of men with prostate cancer.
- More than 30% of prostate cancer patients face recurrence of disease one to four years after removal of the prostate gland.
- The incidence of deaths from prostate cancer was 5.4% for patients who underwent radiation therapy plus hormone treatment, compared with 13.4 percent for those who had only radiation therapy.
- Hormonal treatments could be incorporated into the management of men who need radiation therapy after surgery for prostate cancer.
Adding hormonal therapy which can suppress the growth of tumor in the prostate gland with radiation treatment can significantly improve the average long-term survival of men with prostate cancer who have had their prostate gland removed, according to a new Cedars-Sinai study published in the New England Journal of Medicine. The regimen also can reduce the frequency of spread of the cancer, the study found.
Prostate cancer is the second most common cancer in U.S. men. An estimated 161,300 new cases will be diagnosed and nearly 27,000 deaths are expected in 2017, according to the American Cancer Society.
‘Bicalutamide with GnRH agonists suppress androgen production which stimulates growth of prostate cancer and aggravates recurrence of the disease.’
"Our study indicates that hormonal treatments should be incorporated into the management of men who need radiation therapy after surgery for prostate cancer," said Howard Sandler, MD, chair of the Department of Radiation Oncology the Samuel Oschin Comprehensive Cancer Institute at Cedar's Sinai and senior author of the multicenter study.
More than 30 percent of prostate cancer patients face the return of disease one to four years after removal of the prostate gland, Sandler said.
When a patient experiences a recurrence, physicians typically prescribe radiation therapy. "Our results show that adding hormone therapy could add years to patients' lives," Sandler said.
The hormonal treatment used in the study was designed to suppress male hormones, known as androgens, which can stimulate growth of prostate cancer cells.
The study tracked 761 prostate cancer patients in the U.S. and Canada during a 12-year period after they had participated in a randomized clinical trial of the combined treatment, from 1998 to 2003.
Randomized study participants took the drug daily for two years. The specific drug they received, bicalutamide, has since been supplanted by another drug, GnRH agonists, in clinical practice, Sandler said.
Both drugs suppress hormone production, and presents "proof of principle" that combining hormonal therapy with radiation treatment significantly reduces the rate of metastases and death in the patient group studied.
After 12 years, the incidence of deaths from prostate cancer was 5.4 percent for patients who underwent radiation therapy plus hormone treatment, compared with 13.4 percent for those who had only radiation therapy.
The incidence of prostate cancer metastasis was 14.5 percent for patients who received both treatments, compared with 23 percent for those who had only radiation therapy.
"This important research addressed a significant question in the care of patients with prostate cancer, showing the continued advancement in extending a good quality of life to those patients," said Steven Piantadosi, MD, PhD, director of the Samuel Oschin Comprehensive Cancer Institute.
Sandler said that future studies will explore whether all or only some prostate cancer patients need hormone therapy, the duration of treatment and the role of more powerful hormone therapies.
- Howard Sandler et al., New treatment regimen extends life for some men with recurrent prostate cancer, study finds, New England Journal of Medicine (2017).